Revolution Medicines, Inc.
RVMD- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001628171
In the last 90 days, Revolution Medicines, Inc. insiders filed 0 open-market purchases and 16 sales; 693 institutions reported holding it in 13F filings for Q2 2026, worth $40.1B in total; Duquesne Family Office is the only superinvestor holding it.
Other share classesRVMDW
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Revolution Medicines, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 16 filings
- 9 insiders, $76.6M in total
- Insiders trading
- 9
- Net value
- −$76.6M
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Revolution Medicines, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Mancini Anthony | See Remarks | 39,765 | Sep 28, 2026 | 8 |
| Anderson Elizabeth M | Director | 4,333 | Sep 24, 2026 | 3 |
| Sandler Alan B. | Chief Development Officer | 52,868 | Sep 18, 2026 | 1 |
| Kelsey Stephen Michael | See Remarks | 286,307 | Sep 18, 2026 | 7 |
| Horn Margaret A | Chief Operating Officer | 149,680 | Sep 18, 2026 | 7 |
| Goldsmith Mark A | See Remarks | 253,342 | Sep 18, 2026 | 13 |
| Cislini Jeff | SVP & General Counsel | 52,541 | Sep 18, 2026 | 9 |
| Anders Jack | Chief Financial Officer | 119,216 | Sep 18, 2026 | 9 |
| Kim Lorence H. | Director | 0Indirect | Sep 10, 2026 | 3 |
| Patel Sushil | Director | 21,656 | Jul 1, 2026 | 2 |
| Borisy Alexis | Director | 2,340,075 | Jun 23, 2026 | 1 |
| Horning Sandra | Director | 97,765 | Jun 23, 2026 | 1 |
| Clyburn Frank | Director | 10,929 | Jun 23, 2026 | 1 |
| Borellini Flavia | Director | 26,215 | Jun 23, 2026 | 1 |
| Wang Xiaolin | See Remarks | 116,063 | Mar 19, 2026 | 2 |
| Wei Lin | Chief Medical Officer | 101,366 | Mar 19, 2026 | 2 |
| Schroeder Thilo | Director | 760,869Indirect | Dec 9, 2024 | 0 |
| Weber Barbara | Director | 13,065 | Oct 10, 2024 | 0 |
| Schmidt Eric Thomas | Director | 21,251 | Jun 12, 2023 | 0 |
| Exter Neil | Director | 28,815 | Jun 17, 2022 | 0 |
| Tepper Robert I | 10% Owner | 5,104,130 | Jun 10, 2022 | 0 |
| Third Rock Ventures III, L.P. | 10% Owner | 5,104,130 | Jun 10, 2022 | 0 |
| TRV GP III, LLC | 10% Owner | 5,104,130 | Jun 10, 2022 | 0 |
| Third Rock Ventures GP III, L.P. | 10% Owner | 5,104,130 | Jun 10, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 18, 2026 (view filing)6:00 PM ET | Sep 16 | 2 days | Anders JackChief Financial Officer | SSale | −4.05K | $199.24 | −$807.5K | −3.3%119.2K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:01 PM ET | Sep 16 | 2 days | Cislini JeffSVP & General Counsel | SSale | −3.37K | $199.24 | −$670.6K | −6.0%52.5K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:02 PM ET | Sep 16 | 2 days | Goldsmith Mark ASee Remarks | SSale | −14.0K | $199.24 | −$2.79M | −5.2%253.3K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:03 PM ET | Sep 16 | 2 days | Horn Margaret AChief Operating Officer | SSale | −4.97K | $199.24 | −$989.6K | −3.2%149.7K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:04 PM ET | Sep 16 | 2 days | Kelsey Stephen MichaelSee Remarks | SSale | −5.57K | $199.24 | −$1.11M | −1.9%286.3K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:05 PM ET | Sep 16 | 2 days | Mancini AnthonySee Remarks | SSale | −1.77K | $199.24 | −$353.4K | −4.0%42.1K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:06 PM ET | Sep 16 | 2 days | Sandler Alan B.Chief Development Officer | SSale | −341 | $199.24 | −$67.9K | −0.6%52.9K after | 2 lots10b5-1 |
| Sep 22, 2026 (view filing)6:00 PM ET | Sep 18 | 4 days | Mancini AnthonySee Remarks | SSale | −1.76K | $196.94 | −$347.4K | −4.2%40.4K after | 10b5-1 |
| Sep 24, 2026 (view filing)6:00 PM ET | Sep 22 | 2 days | Anderson Elizabeth MDirector | SSale | −10.1K | $193.04 | −$1.96M | −70.1%4.33K after | 5 lots10b5-1 |
| Sep 28, 2026 (view filing)6:00 PM ET | Sep 24-25 | 4 days | Mancini AnthonySee Remarks | SSale | −3.71K | $200.45 | −$743.3K | −8.5%39.8K after | 2 lots10b5-1 |